Sentences with phrase «median follow»

The median follow - up time was 9 years (range 1 — 10), and medical benefits were received by 986 (13 %) individuals and unemployment benefits by another 676 individuals (9 %).

The authors of a 2008 meta - analysis of prospective cohort studies, including 14 studies reporting on vitamin C for a median follow - up of 10 years, concluded that dietary, but not supplemental, intake of vitamin C is inversely associated with coronary heart disease risk [54].

We calculated the covariates - adjusted number needed to harm associated with each quintile of added sugar intake at 15 - years of follow - up (15 years represents the median follow - up), 39 and the 95 % CI of the number needed to harm was based on 2.5 th and 97.5 th percentile values of 500 rescaled bootstrap weights.40, 41

The number needed to harm at 15 years of follow - up (median follow - up) reduced from 265 (95 % CI, 166 - 715) to 22 (13 - 66)(Table 2).

Among the 11733 participants who met the eligibility criteria for mortality analysis in NHANES III (1988 - 2006), 831 CVD deaths during 163039 person - years of follow - up (median follow - up, 14.6 years) were documented.

One clinical trial with a median follow - up period of 20 years demonstrated that relatively good survival and local control can be achieved in inflammatory breast cancer patients with an aggressive schedule of alternating chemotherapy and radiation treatments.

The median follow - up period was 4.8 years.

A follow - up AREDS2 study confirmed the value of this supplement in reducing the progression of AMD over a median follow - up period of 5 years [75].

Results: During a median follow - up time of 15.8 years (153,103 person years at risk), 1338 incident cases of fatal / non-fatal CVD occurred (672 fatal / non-fatal MI, 545 stroke and 302 HF).

After a median follow - up of five years, either hormone therapy plus Zometa reduced the risk of relapse by 36 percent compared with hormone therapy alone.

Thirteen of 16 patients remain alive with a median follow - up of 78 months.

Follow - up ended December 2013; median follow - up was 5 years.

At a median follow - up of 65 months, both variables independently, negatively predicted disease progression, progression - free survival (PFS) and overall survival (OS).

In this patient set, with a 15.4 - month median follow - up, 82 % of the 108 patients had an objective response and 58 % had a complete response — complete disappearance of their lymphoma.

Median follow - up was 23 · 2 months (IQR 14 · 8 - 28 · 7).

At a median follow - up of 32.9 months (range, 3.6 — 79.2 months), the overall response rate was 86 % for the MBVP group and 86 % for the R - MBVP group.

The mean age was 69.5, 36 % were women, and the median follow - up was 298 days (316 days for intervention group, 217 days for control group).

With a median follow - up of 14 months, patients assigned to combination treatment with cobimetinib and vemurafenib had a progression - free survival of 12.3 months compared with 7.2 months for those on vemurafenib alone.

At data cutoff with a median follow - up of 52.1 weeks, 100 % of patients in the dose - finding phase and 53 % of patients in the dose - expansion phase had confirmed objective responses.

Median duration of response had not been reached after a median follow up of 35.7 months (range: 14.1 to 44.9 months).

The median follow - up for living patients at last contact was 3.73 years.

The 37 % response is not inconsistent with the response rate in some PTSD treatment studies, 37,38 and soldiers may not have had sufficient time to respond to treatment (median follow - up 4 months).

The median follow - up period was 23 months, and QOL was assessed using the Functional Assessment of Cancer Therapy — Breast (FACT - B) and — General (FACT - G), and Euro - QOL - 5 Dimension (EQ - 5D) questionnaires.

In the validation cohort, the median follow - up time was 19.5 months (range, 2.1 — 43.0 months).

[76] An evaluation of 71 patients with metastatic mucosal melanoma treated with ipilimumab through an expanded access program in Italy reported a response rate of 12 % and a disease control rate of 36 % at a median follow - up time of 21.8 months.

The median follow - up period was 16.6 months; results were published in Lancet Oncology.

After a median follow - up of 3.4 years, the 100 - day cumulative incidence rate of grade II to IV acute GVHD was 36 % for the 15 - mg / kg group compared with 29 % for the 30 - mg / kg group (hazard ratio [HR], 0.74; 95 % CI, 0.44 — 1.25; P =.26).

Cohorts A and B had median follow - up periods of 14.5 and 15.1 months, respectively.

The median follow - up was 5.2 years.

After a median follow - up period of 36 months, three patients randomized to continue treatment (17 %) and 10 patients in the discontinuation arm (67 %) had a molecular relapse; all three of the former patients had stopped imatinib treatment after randomization.

The total and median follow - up time for all 3604 patients were 5620 person - years and 1.32 years (interquartile range, 0.57 - 2.34 years), respectively.

Median follow - up for alendronate use was 498 (interquartile range, 228 - 851) days; for no alendronate use, 468 (interquartile range, 187 - 855) days.

Importantly, the survival curves for these groups did not begin to diverge until year 2 or beyond after initial surgery, and continued to widen for the entire 10 - year period, which means preliminary results from the relatively small DeCOG - SLT study — with its 3 - year median follow - up [4]-- can not be relied upon to justify changing the standard of care away from CLND.

Specifically, results from ERSPC document a relative risk reduction of prostate cancer - specific death of 21 % at a median follow - up of 11 years17 While the absolute reduction in prostate cancer - specific mortality was relatively small (0.10 deaths per 1,000 person - years or 1.07 deaths per 1,000 men randomized), this may represent an underestimate of benefit given the length of follow - up of the study and the degree of non-compliance in the intervention arm.

After a median follow - up of 1.32 years (interquartile range, 0.57 - 2.34 years), there were 27 hip fractures in the alendronate group and 73 in the no - alendronate group, corresponding to incidence rates of 9.5 (95 % CI, 6.5 - 13.9) and 27.2 (95 % CI, 21.6 - 34.2) fractures per 1000 person - years, with an absolute rate difference of − 17.6 (95 % CI, − 24.8 to − 10.4).

With a median follow up of 22 months, the 2 - year overall survival probability was 60.7 % in patients aged 65 years or under and 55.6 % in patients aged over 65 years (P = 0.40).

After a median follow - up of 42 months from diagnosis, the 3 - year PFS rate was 66 %, and overall survival was 89 %.

At a median follow - up of 29 months, 136 patients in the ADT - only group had died versus 101 in the group that received both drugs.

At a median follow up of 213 days, 33.3 percent remained on treatment, and 45.6 percent of patients survived for at least one year, which Sharma noted «is better than anything we've seen in the past.»

Median follow - up of the women in the study was 19.5 months (range 0.8 - 86.3 months).

The single PSA screening intervention detected more prostate cancer cases but had no significant effect on prostate cancer mortality after a median follow - up of 10 years.

Primary outcome: prostate cancer — specific mortality at a median follow - up of 10 years.

Median follow - up was four years (7.2 years for surviving patients).

After a median follow - up of 7.2 years, 144 participants developed breast cancer, and 69 died, of which four were due to breast cancer.

As of October 1, 2012, the median follow - up was 14.1 years.

With a median follow - up of 36.7 months, the researchers found no survival benefit of chemoradiotherapy compared with chemotherapy, with median overall survival from the date of the first randomization of 15.2 months and 16.5 months, respectively.

Five patients remain in complete remission after a median follow - up of 26 months.

About 7 out of every 100 cancer patients developed heart failure during the median follow - up of 8.5 years.

The median follow - up was 6.3 years (range 0.2 to 20.2).

Statistical analysis was used to determine Overall Survival (OS), Disease Specific Survival (DSS) and PSA Failure rates (PSAF), and the median follow - up was more than 11 years.